Evidence map›Paper›PMID 26659587›Full record

ReviewCurrent hematologic malignancy reports2016

Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?

Auro Viswabandya, Rebecca Devlin, Vikas Gupta

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Auro ViswabandyaPrincess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Rebecca DevlinPrincess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Vikas GuptaPrincess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada. vikas.gupta@uhn.ca.
University of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Janus kinase 1/2 (JAK1/2) inhibitor therapy is effective in alleviating myelofibrosis (MF)-related symptoms. However, at present, the only curative therapy for MF patients is hematopoietic cell transplantation (HCT). The decision of whether to proceed with HCT, which carries significant risks, or continue with JAK inhibitor therapy is a complicated one. Nevertheless, careful assessment of patient, disease, and transplant-related factors can guide this decision on a case-by-case basis. Difficult questions arise in the decision-making process such as age limits, whether lower-risk patients are suitable candidates, and HCT in patients responding well to JAK inhibitor therapy. The optimal timing of transplant is a major dilemma in the management of MF patients who are responding to or are stable on JAK inhibitor therapy. In this paper, we provide our perspective on selection of transplant versus non-transplant therapies in the management of MF.

Indexed as

Hematopoietic Stem Cell TransplantationDisease ManagementHumansJanus Kinase 1Janus Kinase 2Leukemia, Myeloid, AcuteNitrilesPrimary MyelofibrosisProtein Kinase InhibitorsPyrazolesPyrimidinesTransplantation, HomologousJAK1 protein, humanJAK2 protein, humanJanus Kinase 1Janus Kinase 2NitrilesProtein Kinase InhibitorsPyrazolesPyrimidinesruxolitinibJAK inhibitorsJAK mutationMyelofibrosisOutcomesTransplantation

Identifiers

PMID26659587
OpenAlexW2191051211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.